Stay updated on Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial

Sign up to get notified when there's something new on the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    Locations section updated with numerous new sites across the United States (California, Massachusetts, New Jersey, New York, Ohio, Tennessee, Texas) and China (Anhui, Beijing Municipality, Chongqing Municipality, Fujian, Guangdong, etc.), plus the revision tag v3.3.3. Old location entries appear to have been replaced to reflect the current site list.
    Difference
    2%
    Check dated 2025-12-23T20:33:23.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    No Change Detected
  4. Check
    32 days ago
    Change Detected
    Summary
    Minor wording changes in the Publications section and a page revision label (Revision: v3.3.2) were added; these do not affect core study information. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-11-24T21:39:05.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    The government funding status notice was removed from the page. This change shifts administrative content but does not modify the study details or results.
    Difference
    0.2%
    Check dated 2025-11-17T19:54:25.000Z thumbnail image
  6. Check
    47 days ago
    Change Detected
    Summary
    Taiwan study sites were updated: Tainan City, Taiwan, 704 and 710 were removed and replaced with Tainan, Taiwan, 704 and 710.
    Difference
    0.0%
    Check dated 2025-11-10T17:21:01.000Z thumbnail image
  7. Check
    54 days ago
    Change Detected
    Summary
    The Study Details page for NCT03412773 appears the same in both screenshots, with no changes to the main study information.
    Difference
    0.2%
    Check dated 2025-11-03T13:22:48.000Z thumbnail image
  8. Check
    68 days ago
    Change Detected
    Summary
    Added detailed trial results and substudy information for the tislelizumab vs sorafenib study (RATIONALE-301), including endpoints, locations, and Japanese safety run-in; removed reference to the 2024-01-10 results submission page in favor of the updated results-centric content.
    Difference
    100%
    Check dated 2025-10-20T07:22:25.000Z thumbnail image

Stay in the know with updates to Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page.